Key result
Arrhythmia gene therapy requires further technological innovation for safe and lasting transfer before clinical use.
Why the study?
Existing treatments for tachyarrhythmias have limited efficacy, refractory cases, or lack curative potential, necessitating novel therapies such as gene therapy.
Does gene therapy provide a viable treatment option for tachyarrhythmias refractory to present treatments?
Does gene therapy provide a viable treatment option for tachyarrhythmias refractory to present treatments?
Gene therapy represents a promising future treatment for refractory tachyarrhythmias, though significant technological hurdles remain before clinical application.
Gene therapy should not yet change practice for refractory tachyarrhythmias; leaves open the need for targeted delivery innovations in future studies.
INTRODUCTION: To date, the treatment option for tachyarrhythmia is classified into drug therapy, catheter ablation, and implantable device therapy. However, the efficacy of the antiarrhythmic drugs is limited. Although the indication of catheter ablation is expanding, several fatal tachyarrhythmias are still refractory to ablation. Implantable cardioverter-defibrillator increases survival, but it is not a curable treatment. Therefore, a novel therapy for tachyarrhythmias refractory to present treatments is desired. Gene therapy is being developed as a promising candidate for this purpose, and basic research and translational research have been accumulated in recent years. AREAS COVERED: This paper reviews the current state of gene therapy for arrhythmias, including susceptible arrhythmias, the route of administration to the heart, and the type of vector to use. We also discuss the latest progress in the technology of gene delivery and genome editing. EXPERT OPINION: Gene therapy is one of the most promising technologies for arrhythmia treatment. However, additional technological innovation to achieve safe, localized, homogeneous, and long-lasting gene transfer is required for its clinical application.
No takes yet. Share an insight, caveat, or question.
Kawajiri et al. (2022) conducted a review in Tachyarrhythmias. Gene therapy was evaluated. Gene therapy is a promising technology for arrhythmia treatment, but requires additional technological innovation for safe, localized, homogeneous, and long-lasting gene transfer before clinical use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: